3 days Ago By ABMN Staff
California Public Employees Retirement System cut its stake in shares of Elanco Animal Health Incorporated ( NYSE:ELAN – Free Report ) by 5.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 801,637 shares of the company’s stock after selling 46,454 shares during the period.
California Public Employees Retirement System’s holdings in Elanco Animal Health were worth $9,708,000 as of its most recent SEC filing. Other institutional investors and hedge funds have also added to or reduced their stakes in the company. HighTower Advisors LLC grew its position in shares of Elanco Animal Health by 34.
0% during the 3rd quarter. HighTower Advisors LLC now owns 16,119 shares of the company’s stock worth $237,000 after buying an additional 4,093 shares during the period. Quantinno Capital Management LP increased its stake in Elanco Animal Health by 66.
5% in the third quarter. Quantinno Capital Management LP now owns 250,834 shares of the company’s stock valued at $3,685,000 after purchasing an additional 100,183 shares in the last quarter. Stifel Financial Corp increased its stake in Elanco Animal Health by 82.
4% in the third quarter. Stifel Financial Corp now owns 112,102 shares of the company’s stock valued at $1,647,000 after purchasing an additional 50,637 shares in the last quarter. State Street Corp raised its holdings in Elanco Animal Health by 2.
6% in the third quarter. State Street Corp now owns 9,912,693 shares of the company’s stock worth $145,617,000 after purchasing an additional 255,084 shares during the period. Finally, Wellington Management Group LLP boosted its position in shares of Elanco Animal Health by 19.
2% during the third quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after purchasing an additional 646,522 shares in the last quarter. Institutional investors own 97.
48% of the company’s stock. Wall Street Analysts Forecast Growth Several brokerages recently commented on ELAN. Stifel Nicolaus dropped their price objective on Elanco Animal Health from $18.
00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Barclays dropped their price target on Elanco Animal Health from $20.
00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. UBS Group lowered their target price on Elanco Animal Health from $18.
00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Piper Sandler dropped their target price on shares of Elanco Animal Health from $16.
00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, March 6th. Finally, Morgan Stanley reduced their price target on shares of Elanco Animal Health from $14.
00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company.
According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $15.17.
Elanco Animal Health Trading Down 5.7 % NYSE:ELAN opened at $9.17 on Monday.
The company has a market cap of $4.55 billion, a P/E ratio of 22.91, a price-to-earnings-growth ratio of 2.
50 and a beta of 1.44. Elanco Animal Health Incorporated has a twelve month low of $8.
80 and a twelve month high of $18.80. The business has a 50 day moving average price of $11.
04 and a two-hundred day moving average price of $12.27. The company has a quick ratio of 1.
31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.
Elanco Animal Health ( NYSE:ELAN – Get Free Report ) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.
15 by ($0.01). Elanco Animal Health had a return on equity of 6.
78% and a net margin of 4.60%. The business had revenue of $1.
02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the company posted $0.
08 EPS. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year.
As a group, analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year. Insider Activity In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th.
The stock was acquired at an average cost of $10.20 per share, with a total value of $102,000.00.
Following the completion of the purchase, the director now owns 111,459 shares of the company’s stock, valued at $1,136,881.80. This represents a 9.
86 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link . 0.
57% of the stock is owned by corporate insiders. Elanco Animal Health Profile ( Free Report ) Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Further Reading Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated ( NYSE:ELAN – Free Report ). Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.
com's FREE daily email newsletter ..
